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The vaccinia virus (VACV) E3 protein is essential for virulence and has antiapoptotic activity and the ability
to impair the host innate immune response. Here we demonstrate that E3 interacts with SUMO1 through a
small ubiquitin-like modifier (SUMO)-interacting motif (SIM). SIM integrity is required for maintaining the
stability of the viral protein and for the covalent conjugation of E3 to SUMO1 or SUMO2, a modification that
has a negative effect on the E3 transcriptional transactivation of the p53-upregulated modulator of apoptosis
(PUMA) and APAF-1 genes. We also demonstrate that E3 is ubiquitinated, a modification that does not
destabilize the wild-type protein but triggers the degradation of an E3-SIM mutant. This report constitutes
the first demonstration of the important roles that both SUMO and ubiquitin play in the regulation of the
VACV protein E3.
The vaccinia virus (VACV) E3L gene encodes two proteins
of about 20 and 25 kDa (referred to as E3) that are expressed
early in infection (71) and are present in both the nucleus and
cytoplasm of infected and transfected cells. E3 is a double-
stranded RNA (dsRNA)-binding protein that inhibits the ac-
tivation of interferon (IFN)-induced double-stranded RNA-
dependent protein kinase (PKR) (14) and acts as an inhibitor
of the IFN-induced 2-5A-synthetase enzyme (52). The E3L
gene has been described as being necessary for the VACV
IFN-resistant phenotype in cultured cells (3, 14), host resis-
tance to pathogens in transgenic mice (17), and the inhibition
of apoptosis (39). E3L is also a host range gene necessary for
efficient VACV replication in several cell lines (2). In addition
to these functions, E3 acts as a transcriptional regulator of
several genes related to apoptosis, the immune response, and
viral pathogenesis (9, 34, 36). Posttranslational modifications
are common mechanisms for the regulation of multifunctional
proteins. Thus far, no posttranslational modifications of E3
have been described.
One type of virus-host interaction that is well established
and widespread is the modulation of viral protein function
by posttranslational modification systems, which include
SUMOylation and ubiquitination. Viral proteins were among
the first substrates found to be posttranslationally modified
by the small ubiquitin-like modifier (SUMO) protein, and
SUMOylation seems to facilitate viral infections of the host
cells (8). SUMO is a member of the larger family of ubiquitin-
like proteins, which shares about 18% sequence identity to
ubiquitin and is structurally quite similar (31). Posttransla-
tional modification with ubiquitin and ubiquitin-like proteins
of the SUMO family involves isopeptide bond formation be-
tween the carboxyl group of the modifier and the epsilon-
amino group of a lysine residue in the target. Like ubiquitin,
SUMO is covalently attached to lysine residues within the
target protein, although in the majority of cases, SUMO is
attached to a lysine within the KxE consensus site (where  is
hydrophobic and x is any residue) (5, 55). In mammals, there
are four SUMO isoforms, including SUMO1, which most
closely resembles the single yeast Smt3. SUMO2 and SUMO3,
which are very similar to each other, contain an internal
SUMOylation consensus site and more readily form poly-
SUMO chains (44, 61), and SUMO4 has been linked to dia-
betes (26). SUMOylation regulates a wide range of processes,
including transcriptional activity, protein stability, and nucleo-
cytoplasmic transport. In addition, SUMOylation often pro-
motes interactions between modified proteins and downstream
factors containing SUMO-interacting motifs (SIMs) (22). To
date, a single conserved SIM has been identified, which con-
sists of a hydrophobic core (L/V/I)x(L/V/I)(L/V/I). This SIM
has been detected in several cellular and viral proteins known
to be modified by SUMO, and it was previously shown to be
important for the formation of SUMO-dependent protein net-
works (41, 58).
There are viruses belonging to several different families that
also utilize or modulate the ubiquitin-proteasome system to
their advantage. Proteins can be monoubiquitinated, or the
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initial ubiquitin monomer may itself act as a target, generating
polyubiquitin chains. Distinct polyubiquitin signals that act in
different cellular processes can be created by a variation in the
choice of lysine linkage between ubiquitin monomers or in the
length of the ubiquitin chain used.
The present investigation demonstrates that VACV protein
E3 interacts with SUMO1 and can be covalently modified by
either SUMO1 or SUMO2. The SUMO modification takes
place on the lysine residues at positions 40 and 99 and nega-
tively regulates E3 transcriptional transactivation on the p53-
upregulated modulator of apoptosis (PUMA) and APAF-1
genes. We demonstrate that the presence of an intact SIM in
E3 is required for its own SUMOylation and for the stability of
the viral protein. We also demonstrate the conjugation of E3 to
ubiquitin, a modification that does not induce the degradation
of wild-type E3 (WT-E3) but triggers the proteasome-medi-
ated degradation of the E3-SIM mutant. E3 is the first ex-
ample of a poxvirus protein regulated by covalent modification
by ubiquitin, by the SUMO1 and SUMO2 proteins, as well as
by noncovalent SUMO interactions. These results provide ev-
idence that ubiquitin and ubiquitin-like proteins are important
for the full biological activity of E3.
MATERIALS AND METHODS
Cell lines, transfections, and virus. MCF-7, HeLa, HEK-293, BSC40, and
BHK-21 cells were maintained in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% fetal calf serum (Gibco), 5 mmol/liter L-glu-
tamine (Invitrogen), and penicillin-streptomycin (Invitrogen). The transfection
of MCF-7 and HEK-293 cells was done by use of FuGene (Roche), and HeLa
cells were transfected with Lipofectamine according to the manufacturer’s in-
structions. The vaccinia virus E3L deletion mutant (VACV-E3L) was previ-
ously described (3) and was kindly provided by Enzo Paoletti. This virus was
grown and titrated using BHK-21 cells.
Plasmids and reagents. Plasmid pCINEO-E3 was previously described (20).
All site-directed mutagenesis procedures were carried out by use of the
QuikChange PCR-based mutagenesis kit (Stratagene, La Jolla, CA) and plasmid
pCINEO-E3 as a template. Oligonucleotides used for site-directed mutagenesis
are listed in the supplemental material. pcDNA-His6-SUMO1, pcDNA-His6-
SUMO2, pcDNA-Ubc9, pcDNA-His-ubiquitin, and glutathione S-transferase
(GST)-ISG15 plasmids were previously described (16, 63, 67, 68).
In vitro SUMO conjugation assay. In vitro SUMO conjugation assays were
performed on [35S]methionine-labeled in vitro-transcribed/translated E3 proteins
as described previously (10), using recombinant E1 (Biomol), Ubc9, and SUMO1
or SUMO2. The in vitro transcription/translation of proteins was performed by
using 1 g of plasmid DNA and a rabbit reticulocyte-coupled transcription/
translation system according to the instructions provided by the manufacturer
(Promega).
Western blot analysis and antibodies. For Western blot analysis, cells were
washed in phosphate-buffered saline (PBS), scraped into SDS-gel loading buffer,
and boiled for 5 min. Proteins of total extracts were separated by 12% SDS-
PAGE and transferred onto a nitrocellulose membrane. Mouse anti-E3 antibody
was kindly provided by Bernie Moss (NIH). Rabbit anti-E3 antibody against a
full-length protein expressed in Escherichia coli was produced by Biomedal
(Spain). Mouse anti-SUMO1 antibody was obtained from Invitrogen. Rabbit
anti-SUMO2 antibody was obtained from Zymed Laboratories. Both secondary
Alexa 488-conjugated anti-mouse antibody and Alexa 594-conjugated anti-rabbit
antibody were obtained from Invitrogen. Rabbit anti-vaccinia virus antibodies
were generated against purified inactivated virus of the WR strain.
Immunofluorescence staining. Immunofluorescence staining and confocal
analysis were performed as described previously (10). Colocalization analysis was
done by use of Laser Pix (Image Pro) software. Images were exported by use of
Adobe Photoshop.
Purification of His-tagged conjugates. The purification of His-tagged conju-
gates using Ni2-nitrilotriacetic acid (NTA)-agarose beads was performed as
described previously (43).
GST pulldown. GST pulldown experiments were performed by using protein
extracts obtained from cells transfected with WT-E3 or E3-SIM expression
plasmids and treated with the proteasome inhibitor MG132 and GST or GST-
SUMO1 as described previously (43).
dsRNA-agarose-binding assay. Poly(I:C)-agarose beads were prepared from
poly(I)-coated beads (Sigma) by incubation with 2 volumes of 2 mg of poly(C)
(Sigma) per ml. The agarose beads were then mixed with the in vitro-translated,
radiolabeled protein. After incubation for 1 h at 4°C, the beads were collected by
centrifugation, washed four times with lysis buffer, resuspended in SDS sample
buffer, and then analyzed by electrophoresis (SDS-PAGE) and autoradiography.
Reporter gene assays. MCF-7 cells were transfected with the indicated plas-
mids in 24-well plates. The total DNA was kept equal for all transfections by
using the empty pCINEO vector, and the pRL-TK Renilla luciferase (luc) control
vector (Promega) was cotransfected to determine transfection efficiencies. Cells
were harvested 48 h after transfection, and luciferase activity was measured by
using the Dual Luciferase reporter assay (Promega) according to the manufac-
turer’s instructions. Triplicate measurements were done for all experiments, and
each experiment was repeated at least three times.
RESULTS
E3 protein colocalizes with SUMO1 in VACV-infected cells.
SUMO1 was reported previously to translocate to the viral
factory in response to VACV infection (49). In addition,
SUMO1 was previously isolated as an E3-interacting protein in
a yeast two-hybrid assay (53). Based on these observations, we
decided to study the putative colocalization between SUMO1
and E3 in the viral factories. First, MCF-7 cells were infected
with VACV, and at 4 h after infection, cells were immuno-
stained by using anti-vaccinia virus and anti-SUMO1 antibod-
ies. SUMO1 was localized mainly in a nuclear speckled pattern
in mock-infected cells, as expected (Fig. 1A). In contrast, in
those cells infected with VACV, SUMO1 was recruited to the
viral factories (Fig. 1A). When infected cells, as described
above, were stained with anti-E3 and anti-SUMO1 antibodies,
confocal analysis demonstrated a clear colocalization of both
the E3 and SUMO1 proteins in the viral factories (Fig. 1B).
E3 protein is covalently modified by SUMO. To further
analyze whether E3 can be covalently modified by SUMO, an
in vitro SUMOylation assay was then carried out by using
[35S]methionine-labeled E3 protein as a substrate. As ex-
pected, in vitro-translated E3 was detected as two bands of
around 15 and 22 kDa (Fig. 2A). The incubation of the
SUMOylation reaction mixture with SUMO1 led to the ap-
pearance of additional higher-molecular-mass bands that cor-
responded to E3-SUMO1 (Fig. 2A, left, arrowheads). In addi-
tion, when the in vitro SUMOylation reaction mixture was
incubated in the presence of SUMO2, a ladder of higher-
molecular-mass bands was observed (Fig. 2A, left). To further
prove that E3 is in fact SUMOylated in vitro, E3-SUMO2
obtained as described above was incubated in a deSUMOyla-
tion reaction mixture in the presence of GST or GST-SENP1
(Biomol), a SUMO-specific protease containing the catalytic
domain of SENP1. The incubation of E3-SUMO2 in the pres-
ence of SENP1 led to the disappearance of the higher-molec-
ular-mass bands corresponding to E3-SUMO2 (Fig. 2A, right),
demonstrating that in vitro-synthesized E3 is covalently conju-
gated to SUMO. In order to analyze whether E3 is also
SUMOylated in vivo, HEK-293 cells were cotransfected with a
plasmid encoding E3 together with pcDNA, Ubc9 and
pcDNA-His6-SUMO1, or Ubc9 and pcDNA-His6-SUMO2,
and whole-protein extracts or nickel column-purified histidine-
tagged proteins were then analyzed by Western blotting using
an anti-E3 antibody. Cells cotransfected with pCINEO-E3 and
pcDNA showed two bands of around 15 and 22 kDa, as ex-
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pected (Fig. 2B). However, when His6-SUMO1 was cotrans-
fected with E3, higher-molecular-mass bands of the expected
size were detected in the purified extracts (Fig. 2B, left, arrow-
heads). Analysis of extracts from the His6-SUMO2-transfected
cells also revealed additional bands already visible in crude
extracts that corresponded to E3-SUMO2, as demonstrated
after Western blot analysis of the purified extracts (Fig. 2B,
right). Note that since the levels of SUMO1-modified E3 were
lower than the levels of SUMO2-modified E3, we required
larger amounts of purified protein and longer exposure times
to detect the E3-SUMO1 bands. Moreover, to demonstrate
that E3 is also SUMOylated when produced by the virus,
HEK-293 cells transfected with pcDNA, Ubc9 and pcDNA-
His6-SUMO1, or Ubc9 and pcDNA-His6-SUMO2 were in-
fected with VACV. Whole-cell extracts and histidine-tagged
proteins recovered on nickel beads were analyzed by Western
blotting with an anti-E3 antibody. Upon the purification of
His-tagged complexes, two major E3-SUMO1 conjugates and
several E3-SUMO2 bands were detected (Fig. 2C). Consistent
with the data obtained after the analysis of E3 following trans-
fection, SUMO2 more readily modified E3 than SUMO1. Al-
together, these data demonstrate that the VACV E3 protein is
SUMOylated by SUMO1 and SUMO2 in vitro and in vivo.
SUMO conjugation modulates the transactivation activity
of E3 on the PUMA and APAF-1 genes. Having determined
that VACV E3 is SUMO modified, we sought to identify the
region of E3 involved in this modification. Many SUMO-mod-
ified proteins characterized to date are modified at lysine res-
idues that exist within the KxE consensus sequence (where 
is a hydrophobic residue, K is the modified lysine, x is any
amino acid, and E is glutamic acid). Analysis of the amino acid
sequence using SUMOylation prediction programs revealed a
consensus sequence for SUMOylation, 39EKRE42, that is
highly conserved among distantly related poxviruses (see Fig.
S1 in the supplemental material) and at least one other puta-
tive nonconsensus SUMO conjugation domain located in po-
sition K99 as putative SUMO acceptor sites. To investigate
whether these were the sites for SUMO modification, we con-
structed an E3 point mutant in which lysine 40 or 99 was
replaced with arginine (E3-K40R and E3-K99R). In addition,
an E3 mutant with a mutation in both lysine residues was
generated (E3-K40RK99R), and in vitro SUMO conjugation
FIG. 1. VACV E3 colocalizes with SUMO1 in viral factories. (A) SUMO1 is recruited to viral DNA replication sites. Uninfected cells or MCF-7
cells infected with VACV for 6 h were fixed and stained with DAPI (4,6-diamidino-2-phenylindole) and anti-SUMO1 and anti-vaccinia virus
antibodies. (B) SUMO1 colocalizes with E3 in viral factories. MCF-7 cells infected with VACV for 6 h were fixed and stained with DAPI and
anti-SUMO1 and anti-E3 antibodies. The images were analyzed by confocal microscopy.
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assays using the different E3 mutants as substrates were then
carried out. The conjugation of SUMO1 was clearly reduced in
the E3-K40R mutant, as revealed by the lower levels of the
main E3-SUMO1 bands detected in the assay (Fig. 3A, left).
E3 SUMOylation was not affected by the substitution of lysine
99. However, the double mutation of K40 and K99 to arginine
dramatically reduced the SUMOylation of E3 (Fig. 3A, left).
Results observed after in vitro SUMO2 modification assays
with the E3 mutants revealed similar results. The conjugation
of SUMO2 to the E3-K40R mutant was clearly reduced in
comparison with that observed with WT-E3, and although the
modification of E3-K99R with SUMO2 was quite similar to
that observed with WT-E3, the mutation of both lysines
showed a more significant reduction in SUMO2 conjugation
(Fig. 3A, right). To determine whether these two lysines
are also implicated in SUMOylation in vivo, HEK-293 cells
were cotransfected with pCINEO-E3-WT or pCINEO-E3-
K40RK99R together with pcDNA or Ubc9 and pcDNA-His6-
SUMO2, and analyses of the whole-protein extracts and of the
nickel-purified histidine-tagged proteins using an anti-E3 an-
tibody were carried out. A clear reduction in the E3-
K40RK99R SUMO2 modification in comparison with that of
WT-E3 was observed (Fig. 3B). In addition, the main E3-
SUMO1 band detected in the cells cotransfected with SUMO1
and WT-E3 was not detected in those cells transfected with the
E3-K40RK99R mutant (see Fig. S2 in the supplemental ma-
terial). Altogether, these results indicated that E3 can be mod-
ified by SUMO at both residues. Covalent SUMO conjugation
may regulate the subcellular localization or stability of the
target proteins. In order to analyze if an E3 mutant with a
reduced ability to be SUMOylated has an altered subcellular
localization, MCF-7 cells were transfected with the plasmid
encoding WT-E3 or the E3-K40RK99R mutant, and 36 h after
transfection, cells were stained with an anti-E3 antibody. We
could not detect significant differences in the subcellular local-
izations of both proteins (see Fig. S3 in the supplemental
material). In addition, we did not observe any alteration in the
subcellular localization of E3 after the cotransfection of
pCINEO-E3-WT with SUMO1 or SUMO2 (data not shown).
The effect of SUMOylation on the stability of E3 was then
studied. MCF-7 cells were cotransfected with plasmids encod-
ing WT-E3 or E3-K40RK99R together with pcDNA, Ubc9 and
SUMO1, or Ubc9 and SUMO2 and treated with cyclohexi-
mide, and at different times after treatment, levels of E3 were
analyzed. We could not detect differences in the stabilities of
WT-E3 and the E3-K40RK99R mutant or after the cotrans-
fection of SUMO1 or SUMO2 (see Fig. S4 in the supplemental
material). Furthermore, the stability of E3-SUMO2 was simi-
lar to that of the unmodified E3 protein (Fig. S4), indicating
that SUMOylation does not modulate E3 stability. VACV with
E3L deleted (VACV-E3L) cannot replicate in HeLa cells,
but this host-range phenotype could be complemented by an
E3L gene expressed transiently from a plasmid (13). In addi-
tion, we also observed that VACV-E3L has a replication
defect in HEK-293 cells (see Fig. S5 in the supplemental ma-
terial). Hence, the requirement of E3 SUMO conjugation for
VACV-E3L reconstitution in HeLa or HEK-293 cells was
analyzed. Cells were transfected with pcDNA, WT-E3, or E3-
K40RK99R, and 48 h after transfection, cells were infected
with VACV-E3L at a multiplicity of infection (MOI) of 7.5
PFU per cell. The synthesis of viral proteins 16 h after infec-
tion and VACV production 24 h after infection were deter-
mined. The VACV titer recovered from E3-K40RK99R-trans-
fected HeLa or HEK-293 cells was significantly higher than
that recovered from pcDNA-transfected cells and similar to
the viral titer obtained from WT-E3-transfected cells (Fig. S5).
As expected, no VACV protein synthesis was observed in cells
FIG. 2. Covalent modification of E3 by SUMO1 or SUMO2 in vivo
and in vitro. (A, left) In vitro-translated E3 was used as substrate in an
in vitro SUMOylation assay in the presence of SUMO1 or SUMO2.
(Right) Deconjugation of SUMO2 from E3 by SENP1. (B) HEK-293
cells were cotransfected with pCINEO-E3 together with pcDNA,
pcDNA-Ubc9 and pcDNA-His6-SUMO1, or pcDNA-Ubc9 and
pcDNA-His6-SUMO2. Total protein extracts and histidine-tagged
proteins purified by use of nickel columns were then analyzed by
Western blotting (WB) with an anti-E3 antibody. (C) HEK-293 cells
were transfected with pcDNA, pcDNA-Ubc9 and pcDNA-His6-
SUMO1, or pcDNA-Ubc9 and pcDNA-His6-SUMO2 and then in-
fected with VACV for 5 h. Total protein extracts and histidine-tagged
proteins purified by use of nickel columns were then analyzed by
Western blotting with an anti-E3 antibody. Arrowheads refer to E3-
SUMO1.
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transfected with pcDNA. However, the synthesis of viral pro-
teins in VACV-E3L-infected cells was restored after the ex-
pression of WT-E3 from the transfected plasmid, and viral
protein synthesis was similarly observed after the expression of
the E3-K40RK99R mutant in HeLa or HEK-293 cells (Fig.
S5). Altogether, these results suggest that the SUMO modifi-
cation of E3 is not required for efficient VACV replication.
SUMO conjugation may also alter the transactivation activity
FIG. 3. Role of E3 SUMOylation in transcriptional activity. (A) [35S]methionine-labeled wild-type or mutant E3 proteins were used as
substrates in an in vitro SUMOylation assay in the presence of SUMO1 or SUMO2. The reaction products were visualized by autoradiography.
(B) Total extracts or histidine-tagged purified proteins were prepared from HEK-293 cells cotransfected with pCINEO-E3-WT or E3-K40RK99R
together with pcDNA or pcDNA-Ubc9 and pcDNA-His6-SUMO2, and an immunoblot analysis with an anti-E3 antibody was carried out. (C and
D) MCF-7 cells were transiently transfected in triplicate with the luciferase reporter PUMA-luc together with the plasmids indicated. The same
results were obtained in at least three different experiments. Data represent means  standard errors (SE) for one experiment. *, P  0.05; **,
P  0.005 (compared with WT-E3-transfected cells; determined by the Student test). The right panel represents the expression levels of the E3L
gene transfected in each experiment. (E) MCF-7 cells were transiently transfected in triplicate with the luciferase reporter APAF-luc together with
the plasmids indicated. The same results were obtained in at least three different experiments. Data represent means  SE for one experiment.
(F) Ratio of the level of transactivation of APAF-1–luc by WT-E3 or E3-K40RK99R and SENP-1 to the level of transactivation by WT-E3 or
E3-K40RK99R alone, respectively. The same results were obtained in at least three different experiments. Data represent means  SE for one
experiment. *, P  0.05 (compared with WT-E3 transfected cells; determined by the Student test).
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of the target proteins. Therefore, we were interested in testing
whether a covalent modification by SUMO had any effect on
the transactivation activity of E3. The N terminus of E3 was
suggested previously to stabilize Z-DNA in the promoter re-
gions in some genes, such as the p53 gene, resulting in the
transactivation of the gene (34). Consequently, we decided to
analyze whether an E3 mutant with a reduced ability to be
SUMOylated has an altered transactivation activity. Initially,
transactivation assays were performed with MCF-7 cells that
were transfected with reporter plasmid p53-regulated PUMA-
luc together with increasing amounts of pCINEO-E3-WT. As
shown in Fig. 3C, the expression of WT-E3 induced the trans-
activation of the reporter in a dose-responsive manner. Impor-
tantly, the transactivation levels achieved in our experiments
were similar to those previously reported (34). Next, the trans-
activation activity of WT-E3 or E3-K40RK99R after the
cotransfection of SENP1 on PUMA-luc was analyzed. The
cotransfection of SENP1 significantly increased the transacti-
vation of the promoter induced by WT-E3 (Fig. 3D). The
transfection of the E3-K40RK99R mutant induced a slightly
higher but statistically significant transactivation of the pro-
moter than WT-E3, and this activity was not altered after
the cotransfection of SENP1 (Fig. 3D), suggesting that
SUMOylation has a negative effect on the transactivation ac-
tivity of E3. To reinforce these data, we analyzed the transcrip-
tional activity of E3 on a different reporter. We observed that
E3 induced the transactivation of the p53-regulated APAF-1–
luc reporter in a dose-responsive manner (Fig. 3E). The
cotransfection of SENP1 significantly increased the transacti-
vation of the APAF-1–luc reporter induced by WT-E3 but did
not alter the transcriptional activity of the E3-K40RK99R mu-
tant (Fig. 3F). Altogether, these results indicate that SUMO
conjugation negatively regulates the transcriptional activity of
E3 at the PUMA and APAF-1 genes.
The integrity of the SIM domain in E3 is required for its
stability, nuclear localization, and SUMOylation. Recently, it
was demonstrated that several cellular and viral SUMO targets
can also interact noncovalently with SUMO through a SUMO-
interacting motif (SIM). The best-studied SIM contains a hy-
drophobic core sequence consisting of stretches of three or
four hydrophobic valine, leucine, or isoleucine residues plus
one acidic/polar residue at position 2 or 3 (27, 59). The E3
protein presents a domain that resembles a SIM at position
119VTVI122. A putative noncovalent interaction between
SUMO1 and E3 was also suggested after the analysis of the
colocalization between SUMO1 and the E3-K40RK99R mu-
tant in infected cells (see Fig. S6 in the supplemental material).
To investigate the functionality of this putative SIM, we per-
formed site-directed mutagenesis, by which we replaced valine
at positions 119 and 121 and isoleucine at position 122 with
alanine to generate E3-SIM. Based upon previous results for
other proteins such as hDaxx or IE2p86, it was anticipated that
these mutations would disrupt the SIM function (4, 41). Sur-
prisingly, Western blot analysis of cells transfected with E3-
SIM revealed that the mutant protein was almost undetect-
able, and only when the cells were incubated with the
proteasome inhibitor MG132 was the protein detected (Fig.
4A). Similarly, instability of the E3 protein containing both
K40RK99R and SIM mutations was also observed (see Fig. S7
in the supplemental material), indicating that the SIM is re-
quired for maintaining the stability of the E3 protein. To verify
that the SIM domain in E3 is in fact implicated in the nonco-
valent interaction with SUMO1, we then analyzed whether a
SIM domain mutant can bind SUMO1 by using GST pulldown
assays. WT-E3 but not the E3-SIM mutant was efficiently
bound to GST-SUMO1 resin, but it did not adhere to GST
resin, indicating the functionality of the SIM domain (Fig. 4B).
SIMs are expected to play a crucial role in regulating
SUMOylated proteins. In this sense, the SUMOylation of sev-
eral proteins has been found to be SIM dependent, suggesting
that noncovalent SUMO binding may represent a general
mechanism for substrate selection and modification. To ad-
dress the question of whether the SUMOylation of E3 requires
a SIM-mediated interaction with SUMO, we first tested the in
vitro SUMO conjugation of the E3-SIM mutant compared to
WT-E3. Wild-type and mutant E3 proteins were expressed in
vitro and modified in reaction mixtures containing either
SUMO1 or SUMO2. The SUMO1 and SUMO2 modification
efficiencies of the SIM mutant protein were both dramatically
reduced compared with that of WT-E3 (Fig. 4C), and the
mutation of lysine residues 40 and 99 did not further reduce
the SUMO conjugation of E3-SIM (see Fig. S7 in the sup-
plemental material). We then decided to study the effect of the
SIM domain on E3 SUMOylation in vivo. In vivo SUMOyla-
tion assays of WT-E3 or E3-SIM were then carried out in the
presence of MG132. HEK-293 cells were cotransfected with a
plasmid encoding WT-E3 or E3L-SIM together with pcDNA
or with Ubc9 and pcDNA-His6-SUMO2, and whole-protein
extracts and nickel column-purified histidine-tagged proteins
were then analyzed by Western blotting using an anti-E3 an-
tibody. E3-SUMO2 bands detected in those cells transfected
with pCINEO-E3-WT and pcDNA-His6-SUMO2 were not ob-
served for the cells transfected with the pCINEO-E3-SIM
mutant, indicating that the SIM domain in E3 is implicated in
its SUMOylation in vivo (Fig. 4D). Taken together, these re-
sults demonstrate that efficient E3 SUMOylation requires the
SUMO-SIM interface both in vitro and in vivo. An analysis of
the subcellular localization of the WT-E3, E3-SIM, or E3-
K40RK99R-SIM protein after MG132 treatment was also
carried out. As expected, E3 was detected in both the nucleus
and the cytoplasm of the transfected cells. However, the E3-
SIM mutants were retained into the cytoplasm, suggesting
that the SIM domain is also required for E3 nuclear translo-
cation (Fig. 4E and see Fig. S7 in the supplemental material).
Genetic and biochemical experiments suggested that the bio-
logical activity of E3 is derived primarily from its capacity to
bind to dsRNA (12–14, 69), an interaction that also mediates
its binding to ISG15 (25). Therefore, we analyzed the ability of
the E3-SIM mutant to bind to dsRNA. This was assayed by a
poly(I:C)-agarose-binding assay as previously described (37).
Both the 35S-labeled in vitro-synthesized WT-E3 and E3-SIM
proteins bound to dsRNA-agarose but not to agarose alone
(Fig. 4F), indicating that the SIM domain is not required for
the interaction of E3 and dsRNA. In addition, we studied
whether the SIM domain is required for the interaction be-
tween E3 and ISG15. We detected the coimmunoprecipitation
of E3-SIM and ISG15 (see Fig. S8 in the supplemental ma-
terial), indicating that the SIM domain is not required for the
interaction between E3 and ISG15.
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FIG. 4. The SIM domain in E3 is required for its interaction with SUMO, its stability, SUMOylation, and nuclear localization, but it is not
essential to bind dsRNA. (A) HEK-293 cells were transfected with WT-E3 or E3-SIM expression plasmids and treated or not with MG132 for
24 h. Analyses of the protein extracts by Western blotting with an anti-E3 antibody were then carried out. (B) Protein extracts from HEK-293 cells
transfected with WT-E3 or E3-SIM expression constructs and treated with MG132 for 24 h were incubated with GST or GST-SUMO1. Beads
were washed, and the bound proteins were eluted and subjected to electrophoresis and Western blot analysis with an anti-E3 antibody. The input,
representing 10% of the protein extracts, is shown. (C) [35S]methionine-labeled WT-E3 or E3-SIM proteins were used as substrates in an in vitro
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The E3 protein is differentially ubiquitinated depending on
the integrity of a SIM domain. The degradation of the E3-
SIM mutant by a proteasome-mediated mechanism sug-
gested that E3 might also be modified by ubiquitin. In order to
analyze whether E3 can be ubiquitinated, MCF-7 cells were
transfected with pCINEO-E3-WT in the presence or absence
of pcDNA-His6-ubiquitin, and at 36 h posttransfection, West-
ern blot analysis of E3 was carried out. As shown in Fig. 5A,
additional higher-molecular-mass bands were detected in
those cells cotransfected with ubiquitin. Importantly, the West-
ern blot analysis also revealed that the levels of the E3 protein
were not significantly affected by the expression of ubiquitin,
suggesting that E3 ubiquitination does not induce WT-E3 deg-
radation (Fig. 5A). In order to demonstrate that the higher-
molecular-mass bands correspond to E3-ubiquitin, His-binding
proteins were purified from MCF-7 cells transfected as de-
scribed above. Western blot analysis of the purified extracts
using an anti-E3 antibody revealed that the additional bands
detected after the transfection of ubiquitin corresponded with
E3-ubiquitin (Fig. 5B, left). A broad band of the expected
molecular mass that was recognized by the anti-E3 antibody
was also observed after Western blot analysis of histidine-
tagged proteins obtained from cells transfected with His6-ubiq-
uitin and then infected with VACV (Fig. 5B, right), indicating
that the E3 produced by the virus can also be modified by
ubiquitin. Recent studies provided evidence that ubiquitin
chains with different linkages or lengths may work as specific
signals to control distinct molecular processes. To further char-
SUMOylation assay in the presence of SUMO1 (top) or SUMO2 (bottom). The reaction products were visualized by autoradiography. (D) Total
extracts or histidine-tagged purified proteins were prepared from HEK-293 cells cotransfected with pCINEO-E3-WT or pCINEO-E3-SIM
together with pcDNA or pcDNA-Ubc9 and pcDNA-His6-SUMO2, and an immunoblot analysis with an anti-E3 antibody was carried out. (E)
MCF-7 cells were transfected with WT-E3 or E3-SIM expression plasmids and treated with MG132 for 24 h. Cells were then stained with DAPI
and an anti-E3 antibody, and the localization of E3 was detected by confocal microscopy. (F) [35S]methionine-labeled WT-E3 or E3-SIM proteins
were incubated with agarose or poly(I:C)-agarose. Beads were washed, and the bound proteins were eluted and subjected to electrophoresis and
autoradiography. The input, representing 10% of the quantity of protein used for the binding reaction, is shown.
FIG. 5. E3 protein is differentially ubiquitinated depending on the integrity of a SIM domain. (A) MCF-7 cells were transfected with
pCINEO-E3-WT in the presence or absence of pcDNA-His6-ubiquitin as indicated. Analysis of the protein extracts by Western blotting with an
anti-E3 antibody 48 h after transfection was carried out. (B) MCF-7 cells were transfected as indicated above (left) or transfected with
pcDNA-His6-ubiquitin and then infected with VACV for 6 h (right). Whole-protein extracts and histidine-tagged proteins purified by use of nickel
columns were then analyzed by Western blotting with an anti-E3 antibody. Arrowheads refer to ubiquitinated E3. (C) MCF-7 cells were transfected
with WT-E3- or E3L-SIM-expressing plasmids in the presence or absence of pcDNA-His6-ubiquitin and treated with MG132 for 24 h. Analysis
of the whole-protein extracts and the histidine-tagged proteins purified by use of nickel columns was then carried out by Western blotting with an
anti-E3 antibody.
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acterize E3 ubiquitination, we cotransfected MCF-7 cells with
pCINEO-E3-WT or pCINEO-E3-SIM and pcDNA-His6-
ubiquitin and treated the cells with MG132, and 36 h after
transfection, purified histidine-tagged proteins were analyzed
by Western blotting with an anti-E3 antibody. A high-mobility
ubiquitin-positive smear was observed for the cells transfected
with ubiquitin and the E3-SIM mutant in comparison with
the bands detected for those transfected with WT-E3 expres-
sion constructs (Fig. 5C).
DISCUSSION
The VACV E3L gene product is known as an IFN resistance
protein, as a determinant of host range and viral pathogenesis,
and as a modulator of cellular apoptotic and signal transduc-
tion pathways (35, 36, 42). The E3 protein binds to dsRNA,
and this interaction mediates or enhances its binding to ISG15
and PKR, respectively (25, 57). In addition, E3 can bind to
SUMO1 in a yeast two-hybrid assay, although this interaction
was not confirmed at the biochemical level (53). This finding,
together with the observation that SUMO1 is recruited to viral
factories in response to VACV infection (49), prompted us to
investigate the biochemical nature of the interactions of
SUMO and E3. Our results demonstrate that E3 colocalizes
with SUMO1 in the viral factories and that the E3 protein is
modified by the covalent attachment of SUMO1 or SUMO2 in
vitro and in vivo. Importantly, E3 SUMOylation was demon-
strated for transfected as well as for infected cells, indicating
that the SUMOylation of E3 is independent of VACV infec-
tion. Although SUMOylated lysine residues are often found
within FxE consensus sequences, recent proteomics studies
have shown that a considerable part of SUMOylation occurs
on nonconsensus sites (6, 7, 24, 29). Furthermore, it was de-
scribed previously that lysine selection is promiscuous, because
lysine-to-arginine substitutions at preferred SUMO modifica-
tion sites may result in enhanced modification at secondary
sites (18, 41). The mutation of the consensus sequence in E3
(lysine 40) reduced but did not abrogate its SUMOylation.
However, when the two lysines at residues 40 and 99 of E3
were mutated, the SUMOylation of the double mutant was
clearly reduced both in vitro and in vivo. Consequently, these
two lysine residues at positions 40 and 99 were mapped as
major SUMO conjugation sites. The SUMO modification of
proteins has different effects depending on the target protein.
SUMOylation influences the functions of many viral proteins
by modulating their interactions with other proteins and then
regulating their subcellular localizations, as demonstrated pre-
viously for the VACV A40R protein (49). The subcellular
localization of the SUMOylation-negative E3 mutant was not
altered compared to that of wild-type E3. Changes in the
stability of E3 after the mutation of the two SUMO acceptor
lysines or differences in the stabilities of E3-SUMO2 and E3
were not detected. In addition, the transient transfection of the
SUMOylation-negative E3 mutant was able to reconstitute the
replication of VACV-E3L in HeLa and HEK-293 cells, indi-
cating that SUMO modification is not required for productive
viral infection. The lack of an effect of SUMO conjugation on
virus growth was reported previously for the human cytomeg-
alovirus (HCMV) IE2 protein (38). However, this modification
was required for the transactivation function of IE2 (1, 28). A
direct effect of SUMOylation on transcriptional activity has
been reported for several proteins, and this modification typ-
ically represses transactivation activity (66). E3 activates the
transcription of the human p53 gene through Z-DNA binding
(34). In agreement with these data, our results demonstrate
that E3 induces the transcriptional transactivation of the p53-
regulated PUMA-luc and APAF-1–luc reporter plasmids in a
dose-responsive manner. Moreover, the coexpression of
SENP1 or a mutation of the SUMO conjugation lysines po-
tentiates the E3 transactivation activity. Altogether, these re-
sults indicate that SUMO conjugation is a negative regulator of
the transcriptional activation of p53 by E3.
Recently, the existence of known SUMO targets that inter-
act noncovalently with SUMO and contain SUMO-interacting
motifs (SIMs) was demonstrated (32). Intriguingly, E3 con-
tains a hydrophobic region with a sequence conforming to the
(L/V/I)x(L/V/I)(L/V/I) SIM consensus at the C terminus of the
protein. Furthermore, we still detected colocalization between
E3-K40RK99R and SUMO1 in the infected cells, suggesting
that additional motifs in E3 may mediate the interaction with
SUMO1. Although the mutation of the SIM domain did not
alter the ability of E3 to interact with dsRNA or ISG15, anal-
ysis of the SIM E3 mutant showed impaired SUMOylation in
vitro and in vivo that correlated with the noncovalent SUMO-
binding properties. These results demonstrate that the SIM
domain is not required for the interaction of E3 and dsRNA
but that the SUMO-SIM interface is required for efficient E3
SUMOylation, as observed for an increasing number of target
proteins (32, 41, 47, 60). Importantly, the mutation of the E3
SIM domain led to an unstable protein that was degraded by a
proteasome-mediated mechanism. Analysis of the subcellular
localization in the presence of a proteasome inhibitor also
demonstrated that the SIM mutant showed an exclusively cy-
toplasmic localization, in contrast to the nucleocytoplasmic
distribution of the wild-type protein. Although there is a cor-
relation between the cytoplasmic localization and proteasome-
mediated degradation of E3-SIM, a cytoplasmic E3 mutant
reported previously was not described to be an unstable pro-
tein (13). In addition, the overexpression of ubiquitin-specific
protease 7 (USP7/HAUSP), an enzyme that prevents the deg-
radation of different cellular and viral proteins (11, 19, 40, 46,
65), partially rescues E3-SIM from degradation without al-
tering its cytoplasmic localization (see Fig. S9 in the supple-
mental material). Altogether, these results suggest that the
degradation of the E3-SIM protein is not a consequence of its
cytoplasmic localization. A mutation of the SIM domain in the
E3-K40RK99R mutant also led to an alteration of the
SUMOylation, stability, and subcellular localization of the pro-
tein, supporting the idea that a noncovalent SUMO interaction
but not SUMOylation modulates these E3 properties. Nonco-
valent SUMO interactions have been shown to affect the re-
cruitment of proteins into subnuclear structures (45, 58) or
their transcriptional activity (33, 54). Thus far, this is the first
time that the integrity of a SIM domain within a protein has
been demonstrated to be required for its stability.
In a classical model, ubiquitination was associated with pro-
teasome-mediated degradation. We then decided to analyze
whether E3 can be ubiquitinated. Viruses are connected to
ubiquitin in a variety of ways. A role of ubiquitin in the deg-
radation of viral proteins has been demonstrated in the cases
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of the Epstein-Barr virus (EBV) LMP2a, human papillomavi-
rus (HPV) E7, and HPV E2 proteins (30). However, some viral
functions require ubiquitin modification for purposes other
than protein turnover, as exemplified by the role of the ubiq-
uitination of viral proteins in virion budding and release for the
retroviral (HIV) Gag protein (15, 21), the Ebola virus Vp40
protein (70), or the rhadinovirus M protein (27). Recently, it
was reported that poxviruses exploit the ubiquitination ma-
chinery by expressing viral proteins that function as ubiquitin
ligases or regulate cellular ubiquitin ligases (48, 56, 64). In
addition, it was also demonstrated that the proteasome and
ubiquitin are required for poxvirus infection (62). Our results
demonstrate that E3 can be modified by ubiquitin but that this
ubiquitination does not induce wild-type E3 degradation.
Ubiquitin itself possesses several lysines that can be used for
the attachment of another ubiquitin molecule, allowing sub-
strates to be modified with different types of ubiquitin chains
(50, 51). In this sense, the consequences of polyubiquitination
appear to depend on the length of the ubiquitin chain and on
the type of linkage used. It is then tempting to speculate that
the different stabilities observed between the WT-E3 and the
E3-SIM proteins are due to differences in ubiquitin chain
lengths. An analysis of the conjugation of ubiquitin to WT-E3
or E3-SIM revealed that whereas the WT-E3 ubiquitin mod-
ification was quite limited, very long ubiquitin chains were
conjugated to the E3-SIM mutant, reinforcing this hypothe-
sis. Different evidences reveal the existence of cross talk mech-
anisms between the SUMOylation and ubiquitination systems
(23). This is a new example of how SUMO may have a pro-
found effect on the ubiquitination status of proteins. In addi-
tion, these findings provide evidence for specific posttransla-
tional modifications of VACV E3 that might explain some of
the multiple biological effects exerted by E3 through virus-host
cell interactions.
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